Company profile
KHONDRION
Bringing energy to life
- Industry
- Biotechnology Research
- Employees
- 10
- Headquarters
- Nijmegen, Gelderland
- Founded
- 2012
- LinkedIn followers
- 2,940
- Office locations
- 1
KHONDRION company summary
KHONDRION is a company in the Biotechnology Research industry, headquartered in Nijmegen, Gelderland, founded in 2012. On LinkedIn the company has around 10 employees and 2,940 followers. Warmrank detected 15 technologies across 13 categories on khondrion.com, including Cloudflare, CookieYes, Embedly. Its listed specialties include Life cell quantitative imaging, inborn errors of energy metabolism, compound development and testing, mitochondrial medicine, rare disease.
What technology does KHONDRION use?
Warmrank detected 15 technologies on khondrion.com, last checked July 2026. Click any tool to see other companies that use it.
Cloudflare
Google Hosted LibrariesMiscellaneous
HTTP/3
Open GraphAnalytics
Google AnalyticsCookie compliance
CookieYesFont scripts
Google Font APIJavaScript libraries
jQueryPage builders
WebflowSecurity
SSL/TLS certificate authorities
Tag managers
Google Tag ManagerVideo players
YouTubeWebmail
Microsoft 365Widgets
EmbedlyAbout KHONDRION
We are a Phase 3 ready clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, sonlicromanol , is a potential Phase 3 ready first-in-class oral small molecule in clinical development to treat a range of primary mitochondrial diseases. It has been granted Orphan Drug Designation for for all inherited mitochondrial respiratory chain/oxidative phosphorylation disorders in the US en EU. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases
Specialties
Where is KHONDRION located?
KHONDRION lists 1 location.
Compare companies similar to KHONDRION
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
KHONDRION khondrion.com | Biotechnology Research | 10 | 2012 | Nijmegen, Gelderland |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about KHONDRION
What does KHONDRION do?
We are a Phase 3 ready clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, sonlicromanol , is a potential Phase 3 ready first-in-class oral small molecule in clinical development to treat a range of primary mitochondrial diseases. It has been granted Orphan Drug Designation for for all inherited mitochondrial respiratory chain/oxidative phosphorylation disorders in the US en EU. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases
What technology does KHONDRION use?
Warmrank detected 15 technologies on khondrion.com, including Cloudflare, CookieYes, Embedly, Google Analytics, Google Font API, Google Hosted Libraries, Google Tag Manager, Google Trust Services.
How many employees does KHONDRION have?
KHONDRION has around 10 employees on LinkedIn.
Where is KHONDRION headquartered?
KHONDRION is headquartered in Nijmegen, Gelderland.
When was KHONDRION founded?
KHONDRION was founded in 2012.
Build a lead list from companies like KHONDRION
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.